InsiderTrades.com logo
Andrew Perry net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Perry Biography and Net Worth

Insider of G1 Therapeutics
Andrew Perry is the Insider of G1 Therapeutics.

What is Andrew Perry's net worth?

The estimated net worth of Andrew Perry is at least $805.19 thousand as of July 5th, 2024. Perry owns 112,614 shares of G1 Therapeutics stock worth more than $805,190 as of December 5th. This net worth estimate does not reflect any other assets that Perry may own. Additionally, Perry receives a salary of $568,600.00 as Insider at G1 Therapeutics. Learn More about Andrew Perry's net worth.

How old is Andrew Perry?

Perry is currently 51 years old. There are 6 older executives and no younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics is Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer, who is 65 years old. Learn More on Andrew Perry's age.

What is Andrew Perry's salary?

As the Insider of G1 Therapeutics, Inc., Perry earns $568,600.00 per year. There are 3 executives that earn more than Perry. The highest earning executive at G1 Therapeutics is Mr. John E. Bailey Jr., CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Andrew Perry's salary.

How do I contact Andrew Perry?

The corporate mailing address for Perry and other G1 Therapeutics executives is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. G1 Therapeutics can also be reached via phone at (919) 213-9835 and via email at [email protected]. Learn More on Andrew Perry's contact information.

Has Andrew Perry been buying or selling shares of G1 Therapeutics?

Andrew Perry has not been actively trading shares of G1 Therapeutics in the last ninety days. Most recently, Andrew Perry sold 1,337 shares of the business's stock in a transaction on Friday, July 5th. The shares were sold at an average price of $2.51, for a transaction totalling $3,355.87. Following the completion of the sale, the insider now directly owns 112,614 shares of the company's stock, valued at $282,661.14. Learn More on Andrew Perry's trading history.

Who are G1 Therapeutics' active insiders?

G1 Therapeutics' insider roster includes John Bailey, Jr. (CEO), James Hanson (General Counsel), Rajesh Malik (Insider), Andrew Perry (Insider), and Mark Velleca (Director). Learn More on G1 Therapeutics' active insiders.

Andrew Perry Insider Trading History at G1 Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2024Sell1,337$2.51$3,355.87112,614View SEC Filing Icon  
7/5/2023Sell355$2.45$869.7555,945View SEC Filing Icon  
1/4/2023Sell820$5.58$4,575.6021,300View SEC Filing Icon  
See Full Table

Andrew Perry Buying and Selling Activity at G1 Therapeutics

This chart shows Andrew Perry's buying and selling at G1 Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

G1 Therapeutics Company Overview

G1 Therapeutics logo
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $7.15
Low: $7.15
High: $7.15

50 Day Range

MA: $7.13
Low: $7.08
High: $7.15

2 Week Range

Now: $7.15
Low: $1.08
High: $7.19

Volume

N/A

Average Volume

1,701,154 shs

Market Capitalization

$373.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66